Европска Унија - Енглески - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype-1 - immunologicals - sheep - active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.onset of immunity: 21 days after completion of the primary vaccination scheme.duration of immunity: 12 months.

Европска Унија - Енглески - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01 e1 rp, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, immunologicals, immunologicals for bovidae, cattle, inactivated viral vaccines - cattle - active immunisation of cattle from 3 months of age for the prevention* of viraemia caused by bluetongue virus (btv), serotypes 1 and 8.*(cycling value (ct) ≥ 36 by a validated rt-pcr method, indicating no presence of viral genome).

Европска Унија - Енглески - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - sheep - active immunisation of sheep from 1.5 months of age to prevent viraemia caused by bluetongue virus, serotypes 1 and 8.onset of immunity: 21 days after completion of the primary vaccination scheme.duration of immunity: 12 months.

Европска Унија - Енглески - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - immunologicals - sheep - active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

Европска Унија - Енглески - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - abatacept - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid - immunosuppressants - rheumatoid arthritisorencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) including methotrexate (mtx) or a tumour necrosis factor (tnf)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.psoriatic arthritisorencia, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis (psa) in adult patients when the response to previous dmard therapy including mtx has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. polyarticular juvenile idiopathic arthritisorencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pjia) in paediatric patients 2 years of age and older who have had an inadequate response to previous dmard therapy.orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.

Европска Унија - Енглески - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drugs used in diabetes - diabetes mellitus where treatment with insulin is required. insulin human winthrop rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

Европска Унија - Енглески - EMA (European Medicines Agency)

intervet international b.v. - bluetongue virus vaccine, serotype 8 (inactivated) - immunologicals for ovidae - cattle; sheep - sheepfor the active immunisation of sheep from 2.5 months of age to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.cattlefor the active immunisation of cattle from 2.5 months of age to prevent viraemia* caused by bluetongue virus serotype 8.*(cycling value (ct) ≥ 36 by a validated rt-pcr method, indicating no presence of viral genome)

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sol-millennium medical pty ltd - ct936 - specimen receptacle ivds - blood collection tubes are used to collect, transport, and preserve blood for testing serum, plasma, or whole blood in the clinical laboratory.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: dimethyl sulfoxide; sodium chloride; albumin - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients greater than or equal to 18 years of age with relapsed or refractory (r/r) b-cell acute lymphoblastic leukaemia (b-all).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

beigene aus pty ltd - zanubrutinib, quantity: 80 mg - capsule - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; sodium lauryl sulfate; magnesium stearate; gelatin; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid - waldenstr?m?s macroglobulinaemia (wm),brukinsa is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll),brukinsa is indicated as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), including patients with deletion 17p and/or tp53 mutation. mantle cell lymphoma (mcl),brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.,this indication was approved via the provisional approval pathway, based on objective response rate. continued approval for this indication depends on verification and description of clinical benefit in the confirmatory trials.,marginal zone lymphoma (mzl),brukinsa is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one-prior anti-cd20-based therapy.,this indication was approved via the provisional approval pathway, based on objective response rate. continued approval for this indication depends on verification and description of clinical benefit in the confirmatory trials.